Hyloris Pharmaceuticals S.A.
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more
Hyloris Pharmaceuticals S.A. (0AB6) - Net Assets
Latest net assets as of June 2025: €28.89 Million EUR
Based on the latest financial reports, Hyloris Pharmaceuticals S.A. (0AB6) has net assets worth €28.89 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€37.05 Million) and total liabilities (€8.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €28.89 Million |
| % of Total Assets | 77.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -45.57% |
| 10-Year Change | N/A |
| Growth Volatility | 16.35 |
Hyloris Pharmaceuticals S.A. - Net Assets Trend (2019–2024)
This chart illustrates how Hyloris Pharmaceuticals S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hyloris Pharmaceuticals S.A. (2019–2024)
The table below shows the annual net assets of Hyloris Pharmaceuticals S.A. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €32.14 Million | -17.73% |
| 2023-12-31 | €39.07 Million | -29.02% |
| 2022-12-31 | €55.05 Million | +14.54% |
| 2021-12-31 | €48.06 Million | -18.63% |
| 2020-12-31 | €59.06 Million | +679.69% |
| 2019-12-31 | €-10.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hyloris Pharmaceuticals S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5038900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €118.61 Million | 369.02% |
| Total Equity | €32.14 Million | 100.00% |
Hyloris Pharmaceuticals S.A. Competitors by Market Cap
The table below lists competitors of Hyloris Pharmaceuticals S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Major Cineplex Group Public Company Limited
F:MJG1
|
$72.00 Million |
|
Ucore Rare Metals Inc
OTCQX:UURAF
|
$72.00 Million |
|
Leo Systems
TWO:5410
|
$72.05 Million |
|
AZKOYEN SA INH. EO 060
F:AKK
|
$72.11 Million |
|
Victek Co. Ltd
KQ:065450
|
$71.93 Million |
|
Gipta Ofis Kirtasiye ve Promosyon Ãrünleri Imalat Sanayi A.S.
IS:GIPTA
|
$71.91 Million |
|
Somany Ceramics Limited
NSE:SOMANYCERA
|
$71.89 Million |
|
Formet Celik Kapi Sanayi ve Ticaret AS
IS:FORMT
|
$71.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hyloris Pharmaceuticals S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,069,000 to 32,143,000, a change of -6,926,000 (-17.7%).
- Net loss of 6,342,000 reduced equity.
- Other factors decreased equity by 584,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.34 Million | -19.73% |
| Other Changes | €-584.00K | -1.82% |
| Total Change | €- | -17.73% |
Book Value vs Market Value Analysis
This analysis compares Hyloris Pharmaceuticals S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €-0.43 | €6.26 | x |
| 2020-12-31 | €2.29 | €6.26 | x |
| 2021-12-31 | €1.86 | €6.26 | x |
| 2022-12-31 | €1.97 | €6.26 | x |
| 2023-12-31 | €1.40 | €6.26 | x |
| 2024-12-31 | €1.15 | €6.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hyloris Pharmaceuticals S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -74.98%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.29x
- Recent ROE (-19.73%) is below the historical average (-19.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -5904.40% | 0.02x | 0.00x | €-4.35 Million |
| 2020 | -12.10% | -4082.86% | 0.00x | 1.17x | €-13.05 Million |
| 2021 | -24.09% | -374.00% | 0.05x | 1.32x | €-16.38 Million |
| 2022 | -19.57% | -364.96% | 0.05x | 1.12x | €-16.27 Million |
| 2023 | -39.37% | -736.94% | 0.04x | 1.22x | €-19.29 Million |
| 2024 | -19.73% | -74.98% | 0.20x | 1.29x | €-9.56 Million |
Industry Comparison
This section compares Hyloris Pharmaceuticals S.A.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hyloris Pharmaceuticals S.A. (0AB6) | €28.89 Million | 0.00% | 0.28x | $71.96 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |